Placenta growth factor stimulates the growth of Philadelphia chromosome positive acute lymphoblastic leukemia cells by both autocrine and paracrine pathways

European Journal of Haematology

Volumn 75, Issue 4, 2005, Pages 273-279

  Ikai, Toshiko ^a   Miwa, Hiroshi ^a   Shikami, Masato ^a   Hiramatsu, Akihito ^a   Tajima, Emi ^a   Yamamoto, Hidesuke ^a   Imai, Norikazu ^a   Hattori, Akiko ^a   Nishii, Kazuhiro ^b   Miura, Kazuhisa ^a   Satoh, Atsushi ^a   Itoh, Masato ^a   Imamura, Akira ^a   Mihara, Hidetsugu ^a   Katoh, Yoshiro ^a   Nitta, Masakazu ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute lymphoblastic leukemia (ALL); Philadelphia chromosome (Ph); Placenta growth factor (PlGF); Vascular endothelial growth factor receptor type 1 (VEGFR1)

Indexed keywords

FC RECEPTOR; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CELL CYCLE S PHASE; CONTROLLED STUDY; GENE EXPRESSION; HEMATOPOIESIS; HUMAN; HUMAN CELL; PARACRINE SIGNALING; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; PARACRINE COMMUNICATION; PREGNANCY PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; S PHASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 24744450546     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00505.x     Document Type: Article

References (23)

1. FERRARA N, CARVER-MOORE K, CHEN H, DOWD M, LU L, O'SHEA KS, POWELL-BRAXTON L, HILLAN KJ, MOORE MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-442.
2. CARMELIET P, FERREIRA V, BREIER G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-439.
3. SHALABY F, ROSSANT J, YAMAGUCHI TP, GERTSENSTEIN M, WU XF, BREITMAN ML, SCHUH AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Blood 1995;376:62-66.
4. GERBER H-P, MALIK AK, SOLAR GP, SHERMAN D, LIANG XH, MENG G, HONG K, MARSTERS JC, FERRARA N. VEGF regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002;417:954-958.
5. + stem cells from bone-marrow microenvironment. Nat Med 2002;8:841-849.
6. DIAS S, HATTORI K, ZHU Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000;106:511-521.
7. BELLAMY WT, RICHTER L, SIRJANI D, ROXAS C, BETTY GG, FRUTIGER Y, GROGAN TM, LIST AF. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001;97:1427-1434.
8. SANTOS SC, DIAS S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 2004;103:3883-3889.
9. LIST AF, GLINSMANN-GIBSON B, STANDHEIM C, MEUILLET EJ, BELLAMY W, POWIS G. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Exp Hematol 2004;32:526-535.
10. DIAS S, HATTORI K, HEISSIG B, et al. Inhibition of both paracrine and autocrine VEGF/VEGFR2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001;98:10857-10862.
11. AGUAYO A, ESTEY E, KANTARJIAN H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999;11:3717-3721.
12. DE BONT ESJM, ROSATI S, JACOBS S, KAMPS WA, VELLENGA E. Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol 2001;113:296-230.
13. DE BONT ESJM, FIDLER V, MEEUWSEN T, SCHERPEN F, HAHLEN K, KAMPS WA. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 2002;8:2856-2861.
14. MELO JV. The molecular biology of chronic myeloid leukemia. Leukemia 1996;10:751-756.
15. FADERL S, KANTARJIAN HM, TALPAZ M, ESTROV Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998;91:3995-4019.
16. GLEISSNER B, GÖKBUGET N, BARTRAM CR, et al. (The German Multicenter Trials of Adult Acute Lymphoblastic Leukemia Study Group). Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002;99:1536-1543.
17. ANNINO L, GOEKBUGET N, DELANNOY A. Acute lymphoblastic leukemia in the elderly. Hematol J 2002;3:219-223.
18. VAN DONGEN JJM, MACINTYRE EA, GABERT JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia 1999;13:1901-1928.
19. HEROLD-MENDE C, STEINER HH, ANDL T, RIEDE D, BUTTLER A, REISSER C, FUSENIG NE, MUELLER MM. Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab Investig 1999;79:1573-1582.
20. NAKAJIMA-IIJIMA S, HAMADA H, REDDY P, KAKUNAGA T. Molecular structure of the human cytoplasmic β-actin gene: Interspecies homology of sequences in the introns. Proc Natl Acad Sci USA 1985;82:6133-6137.
21. GREEN CJ, LICHTLEM P, HUYNH NT, YANOVSKY M, LADEROUTE KR, SCHAFFNER W, MURPHY BJ. Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. Cancer Res 2001;61:2696-2703.
22. PERSICO MG, VINCENTI V, DIPALMA T. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). Curr Top Microbiol Immunol 1999;237:31-40.
23. HU Y, LIU Y, PELLETIER S, BUCHDUNGER E, WARMUTH M, FABBRO D, HALLEK M, VAN ETTEN RA, LI S. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004;36:453-461.